Stockreport

Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder

UROVANT SCIENCES LTD COMMON  (UROV) 
Last urovant sciences ltd common earnings: 2/13 04:15 pm Check Earnings Report
PDF IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. [Read more]